147 related articles for article (PubMed ID: 10958122)
1. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.
Rogers DC; Costall B; Domeney AM; Gerrard PA; Greener M; Kelly ME; Hagan JJ; Hunter AJ
Psychopharmacology (Berl); 2000 Jul; 151(1):91-7. PubMed ID: 10958122
[TBL] [Abstract][Full Text] [Related]
2. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
3. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
Fukuzaki K; Kamenosono T; Kitazumi K; Nagata R
Pharmacol Biochem Behav; 2000 Sep; 67(1):121-9. PubMed ID: 11113491
[TBL] [Abstract][Full Text] [Related]
4. Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats.
Rogóz Z; Skuza G; Kłlodzińska A
Pol J Pharmacol; 2004; 56(5):519-26. PubMed ID: 15591639
[TBL] [Abstract][Full Text] [Related]
5. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
Dhir A; Kulkarni SK
Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
[TBL] [Abstract][Full Text] [Related]
6. Ropinirole regulates emotionality and neuronal activity markers in the limbic forebrain.
Mavrikaki M; Schintu N; Nomikos GG; Panagis G; Svenningsson P
Int J Neuropsychopharmacol; 2014 Dec; 17(12):1981-93. PubMed ID: 24852388
[TBL] [Abstract][Full Text] [Related]
7. D-512, a novel dopamine D
Lindenbach D; Das B; Conti MM; Meadows SM; Dutta AK; Bishop C
Br J Pharmacol; 2017 Sep; 174(18):3058-3071. PubMed ID: 28667675
[TBL] [Abstract][Full Text] [Related]
8. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.
Reavill C; Boyfield I; Coldwell M; Nelson P
J Pharm Pharmacol; 2000 Sep; 52(9):1129-35. PubMed ID: 11045894
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
Coldwell MC; Boyfield I; Brown T; Hagan JJ; Middlemiss DN
Br J Pharmacol; 1999 Aug; 127(7):1696-702. PubMed ID: 10455328
[TBL] [Abstract][Full Text] [Related]
11. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
[TBL] [Abstract][Full Text] [Related]
12. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists.
Varty GB; Cohen-Williams ME; Morgan CA; Pylak U; Duffy RA; Lachowicz JE; Carey GJ; Coffin VL
Neuropsychopharmacology; 2002 Sep; 27(3):371-9. PubMed ID: 12225694
[TBL] [Abstract][Full Text] [Related]
13. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
14. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation.
Varty GB; Morgan CA; Cohen-Williams ME; Coffin VL; Carey GJ
Neuropsychopharmacology; 2002 Sep; 27(3):357-70. PubMed ID: 12225693
[TBL] [Abstract][Full Text] [Related]
15. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
[TBL] [Abstract][Full Text] [Related]
16. Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist.
Parker SG; Raval P; Yeulet S; Eden RJ
Eur J Pharmacol; 1994 Nov; 265(1-2):17-26. PubMed ID: 7883025
[TBL] [Abstract][Full Text] [Related]
17. Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D
Sałat K; Furgała-Wojas A
Molecules; 2021 Apr; 26(8):. PubMed ID: 33924258
[TBL] [Abstract][Full Text] [Related]
18. Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems.
Zarrindast MR; Mahboobi S; Sadat-Shirazi MS; Ahmadi S
J Psychopharmacol; 2011 Jan; 25(1):131-40. PubMed ID: 20685770
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of dopamine receptor agonists ropinirole and quinpirole on locomotor and anxiolytic behaviors in larval zebrafish (Danio rerio): A role for the GABAergic and glutamate system?
Wengrovitz A; Ivantsova E; Crespo N; Patel M; Souders CL; Martyniuk CJ
Neurotoxicol Teratol; 2023; 98():107183. PubMed ID: 37211288
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
